CLOs on the Move

Telesis Bio Incorporated

www.telesisbio.com

 
Telesis Bio is empowering researchers to accelerate the creation of novel synthetic biology solutions to address some of humanity`s greatest challenges. With our breakthrough automation solutions for biological synthesis and expertise in DNA biology, we enable rapid, accurate, and reproducible writing of DNA and mRNA for wide-ranging biological applications. Around the world, innovators are leveraging Telesis Bio`s technology to overcome current bottlenecks in synthetic biology workflows and advance the discovery of cutting-edge solutions for health and technology. We are proud of our growing collaborations with partners that include premier academic research institutions, emerging start-ups to nearly all of the Top 25 ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.telesisbio.com
  • 10431 Wateridge Circle, Suite 150
    San Diego, CA USA 92121
  • Phone: 858.228.4115

Executives

Name Title Contact Details

Similar Companies

Neurogene

Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families.

DermTech International

DermTech International is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pascal Biosciences

Pascal Biosciences is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The company`s leading cannabinoid portfolio comprises a small molecule therapeutic, ST-403, that is advancing into clinical trials for the treatment of glioblastoma, and an immuno-stimulatory molecule. In addition, Pascal Biosciences is developing a B-cell targeted antibody for acute lymphoblastic leukemia and an antibody for calcium channels expressed by the immune system. Pascal is headquartered in Vancouver, Canada. The company trades on the TSX Venture Exchange under the symbol “PAS”.

CereVasc

The CereVasc eShunt™ device is intended to improve patient outcomes and redefine the treatment of communicating hydrocephalus.

RayzeBio

RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020